All hematologic / cancer diseases. 1st. analysis: colorectal cancer, breast cancer, lung cancer, lymphoma
Conditions
Interventions
Group 1: During the development of the registry, real-life-data from all hematologic / cancer patients should be collected. Especially demographic data (year of birth, gender), disease (incl. the actu
Sponsors
Onkotrakt AG
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: hematologic / cancer patients with medical therapy > 18 years with informed consent
Exclusion criteria
Exclusion criteria: age < 18 years, no written informed consent, or patients which are not able to give consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Examination of the effectiveness and representativity of the newly developed registry 2. patient`s age < 70 vs. =70 years: influence of age on therapy choice or -intensity (percentage of multidrug therapies, duration of therapies, administered courses of therapy per line, mean intervals of cycles, dose modifications) | — |
Secondary
| Measure | Time frame |
|---|---|
| 3) tumour entity: differences in total duration of therapy, lines, modifications of drug dose depending on disease 4) therapy protocol: is there any correlation between therapy duration, therapy protocol and patients age? 5) Intensity and line: in which therapy line do the most dose modifications occur ? | — |
Countries
Germany
Contacts
Public ContactOlga Olschewski
Onkotrakt AG
Outcome results
None listed